jRCT2031240331招募中不适用
Pharmacokinetic study of HP-5120
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 112
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 45age old not（—）
- 性别
- All
入选标准
- •Healthy adult Japanese males and females aged 18 or older and younger than 45 years
- •Subjects weighing 40 kg or more
排除标准
- •Subjects with or with a history of serious cardiovascular, renal, hepatic, gastrointestinal, endocrine, neuropsychiatric, dermatological, metabolic, or immunological disease
- •Subjects who received any drug within 1 week prior to administration of the investigational product
- •Subjects who took any drug considered to affect drug metabolism within 4 weeks prior to administration of the investigational product
结局指标
主要结局
-
Pharmacokinetics, Safety
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Pharmacokinetic study of HP-6050Healthy adult and elderlyJPRN-jRCT2031220536Inakura Hiroshi60
招募中
不适用
Pharmacokinetic study of HP-6050 - Investigation of application site -jRCT2031240538Hisamitsu Pharmaceutical Co., Inc.15
未知
1 期
A clinical pharmacology study of CH5424802 (JP28927)on-small cell lung cancerJPRN-jRCT2080222140Chugai Pharmaceutical Co., Ltd.35
未知
2 期
Phase II clinical study in patients with Parkinson's disease.Parkinson's diseaseJPRN-jRCT2080221631Hisamitsu Pharmaceutical Co., Inc.
已完成
1 期
Evaluation of the Pharmacokinetics of IPX233 Formulations in Healthy VolunteersAttention Deficit Hyperactivity Disorder (ADHD)Neurological - Other neurological disordersACTRN12613001073796Impax Pharmaceuticals,A Division of Impax Laboratories, Inc.20